These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 1687031

  • 1. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
    Ben-Shachar D, Pinhassi B, Youdim MB.
    Eur J Pharmacol; 1991 Sep 17; 202(2):177-83. PubMed ID: 1687031
    [Abstract] [Full Text] [Related]

  • 2. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity.
    Ben-Shachar D, Youdim MB.
    J Neurochem; 1990 Apr 17; 54(4):1136-41. PubMed ID: 1968955
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
    Magnusson O, Fowler CJ, Köhler C, Ogren SO.
    Neuropharmacology; 1986 Feb 17; 25(2):187-97. PubMed ID: 2939362
    [Abstract] [Full Text] [Related]

  • 4. Nutritional iron and dopamine binding sites in the rat brain.
    Ashkenazi R, Ben-Shachar D, Youdim MB.
    Pharmacol Biochem Behav; 1982 Feb 17; 17 Suppl 1():43-7. PubMed ID: 7184034
    [Abstract] [Full Text] [Related]

  • 5. Effect of chronic apomorphine on the development of denervation supersensitivity.
    Robin M, Forler C, Palfreyman MG.
    Pharmacol Biochem Behav; 1985 Apr 17; 22(4):547-51. PubMed ID: 3921992
    [Abstract] [Full Text] [Related]

  • 6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 17; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 7. Iron modulates neuroleptic-induced effects related to the dopaminergic system.
    Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MB.
    Isr J Med Sci; 1993 Sep 17; 29(9):587-92. PubMed ID: 7901181
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of fluperlapine compared with clozapine.
    Eichenberger E.
    Arzneimittelforschung; 1984 Sep 17; 34(1A):110-3. PubMed ID: 6145425
    [Abstract] [Full Text] [Related]

  • 9. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
    Pierce RC, Rowlett JK, Bardo MT, Rebec GV.
    Neuroscience; 1991 Sep 17; 45(2):373-8. PubMed ID: 1762684
    [Abstract] [Full Text] [Related]

  • 10. Characterization of D2 receptors and dopamine levels in the thalamus of the rat.
    Young KA, Wilcox RE.
    Life Sci; 1991 Sep 17; 48(19):1845-52. PubMed ID: 1645835
    [Abstract] [Full Text] [Related]

  • 11. Chronic neuroleptic treatment does not suppress the dynamic characteristics of the dopaminergic receptor D2 system.
    Andia I, Zumarraga M, Retuerto F, Zamalloa I, Davila R.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan 17; 18(1):181-91. PubMed ID: 7906895
    [Abstract] [Full Text] [Related]

  • 12. The behavioral and biochemical effects of lithium on dopaminergic agonist-induced supersensitivity.
    Rubin EH, Wooten GF.
    Psychopharmacology (Berl); 1984 Jan 17; 84(2):217-20. PubMed ID: 6438680
    [Abstract] [Full Text] [Related]

  • 13. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O, Roncada P, Dall'Olio R, Montanaro N.
    Brain Res; 1988 Jul 12; 455(2):390-3. PubMed ID: 2969768
    [Abstract] [Full Text] [Related]

  • 14. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
    Rupniak N, Hong M, Mansfield S, Fleminger S, Dyer R, Jenner P, Marsden CD.
    Eur J Pharmacol; 1983 Sep 30; 93(3-4):195-200. PubMed ID: 6139285
    [Abstract] [Full Text] [Related]

  • 15. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE, Howard SG.
    Eur J Pharmacol; 1990 Aug 10; 184(2-3):257-64. PubMed ID: 2150376
    [Abstract] [Full Text] [Related]

  • 16. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD.
    Biochem Pharmacol; 1983 Oct 01; 32(19):2921-7. PubMed ID: 6138043
    [Abstract] [Full Text] [Related]

  • 17. Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol.
    Lévesque D, Di Paolo T.
    Neurosci Lett; 1988 May 16; 88(1):113-8. PubMed ID: 2969467
    [Abstract] [Full Text] [Related]

  • 18. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H, Sällemark M.
    Pharmacol Toxicol; 1987 May 16; 60(5):359-63. PubMed ID: 2886988
    [Abstract] [Full Text] [Related]

  • 19. Acute and chronic effects of neuroleptics and acute effects of apomorphine and amphetamine on dopamine turnover in corpus striatum and substantia nigra of the rat brain.
    Nicolaou NM.
    Eur J Pharmacol; 1980 Jun 13; 64(2-3):123-32. PubMed ID: 6105080
    [Abstract] [Full Text] [Related]

  • 20. Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolite levels.
    MacRae PG, Spirduso WW, Cartee GD, Farrar RP, Wilcox RE.
    Neurosci Lett; 1987 Aug 18; 79(1-2):138-44. PubMed ID: 2959886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.